Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,880 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.
Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Sonneveld P, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: morel p. Blood. 2017 Jan 26;129(4):456-459. doi: 10.1182/blood-2016-09-742411. Epub 2016 Nov 21. Blood. 2017. PMID: 27872060 Free article. Clinical Trial.
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gaulard P, Coiffier B. Mounier N, et al. Among authors: morel p. Blood. 2003 Jun 1;101(11):4279-84. doi: 10.1182/blood-2002-11-3442. Epub 2003 Feb 6. Blood. 2003. PMID: 12576316 Free article. Clinical Trial.
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.
André M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, Tilly H, Coiffier B, Bosly A, Morel P, Haioun C, Gaulard P, Reyes F, Gisselbrecht C; Groupe D'Etude Des Lymphomes De L'Adulte. André M, et al. Among authors: morel p. Blood. 2004 Feb 15;103(4):1222-8. doi: 10.1182/blood-2003-04-1124. Epub 2003 Oct 23. Blood. 2004. PMID: 14576060 Free article.
Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, Morra E, Cortelazzo S, Bettini R, Merlini G. Gobbi PG, et al. Among authors: morel p. Clin Cancer Res. 2005 Mar 1;11(5):1786-90. doi: 10.1158/1078-0432.CCR-04-1899. Clin Cancer Res. 2005. PMID: 15756000
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, Ilariucci F, Luminari S, Morel P, Merlini G, Gobbi P. Baldini L, et al. Among authors: morel p. J Clin Oncol. 2005 Jul 20;23(21):4662-8. doi: 10.1200/JCO.2005.06.147. J Clin Oncol. 2005. PMID: 16034042
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.
Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, Garcia-Sanz R, Johnson S, Kimby E, Leblond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone MJ. Treon SP, et al. Among authors: morel p. Blood. 2006 May 1;107(9):3442-6. doi: 10.1182/blood-2005-02-0833. Epub 2006 Jan 12. Blood. 2006. PMID: 16410453 Free article.
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, Johnson S, LeBlond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone M, Bladé J. Kimby E, et al. Among authors: morel p. Clin Lymphoma Myeloma. 2006 Mar;6(5):380-3. doi: 10.3816/CLM.2006.n.013. Clin Lymphoma Myeloma. 2006. PMID: 16640813
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister A, Morel P, Matous J, Gregory SA, Kimby E. Treon SP, et al. Among authors: morel p. Blood. 2009 Apr 16;113(16):3673-8. doi: 10.1182/blood-2008-09-177329. Epub 2008 Nov 17. Blood. 2009. PMID: 19015393 Free PMC article. Clinical Trial.
1,880 results